Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK
- PMID: 15494423
- DOI: 10.1182/blood-2004-07-2767
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK
Abstract
Interactions between the Chk1 inhibitor UCN-01 and the farnesyltransferase inhibitor L744832 were examined in human leukemia cells. Combined exposure of U937 cells to subtoxic concentrations of UCN-01 and L744832 resulted in a dramatic increase in mitochondrial dysfunction, apoptosis, and loss of clonogenicity. Similar interactions were noted in other leukemia cells (HL-60, Raji, Jurkat) and primary acute myeloid leukemia (AML) blasts. Coadministration of L744832 blocked UCN-01-mediated phosphorylation of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK), leading to down-regulation of phospho-cyclic adenosine monophosphate responsive element-binding protein (phospho-CREB) and -p90(RSK) and activation of p34(cdc2) and stress-activated protein kinase/ERK kinase/c-Jun N-terminal kinase (SEK/JNK). Combined treatment also resulted in pronounced reductions in levels of phospho-Akt, -glycogen synthase kinase-3 (-GSK-3), -p70(S6K), -mammalian target of rapamycin (-mTOR), -forkhead transcription factor (-FKHR), -caspase-9, and -Bad. Ectopic expression of Bcl-2 or Bcl-xL but not dominant-negative caspase-8 blocked UCN-01/L744832-mediated mitochondrial dysfunction and apoptosis but did not prevent activation of p34(cdc2) and JNK or inactivation of MEK/ERK and Akt. Enforced expression of myristoylated Akt but not constitutively active MEK significantly attenuated UCN-01/L744832-induced apoptosis. However, dual transfection with Akt and MEK resulted in further protection from UCN-01/L744832-mediated lethality. Finally, down-regulation of JNK1 by siRNA significantly reduced the lethality of the UCN-01/L744832 regimen. Together, these findings suggest that farnesyltransferase inhibitors interrupt the cytoprotective Akt and MAPK pathways while reciprocally activating SAPK/JNK in leukemia cells exposed to UCN-01 and, in so doing, dramatically increase mitochondria-dependent apoptosis.
Similar articles
-
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.Mol Cancer Ther. 2005 Mar;4(3):457-70. doi: 10.1158/1535-7163.MCT-04-0137. Mol Cancer Ther. 2005. PMID: 15767555
-
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.Clin Cancer Res. 2005 Jun 15;11(12):4589-600. doi: 10.1158/1078-0432.CCR-04-2346. Clin Cancer Res. 2005. PMID: 15958645
-
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.Cancer Res. 2001 Jul 1;61(13):5106-15. Cancer Res. 2001. PMID: 11431348
-
Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.Curr Med Chem. 2011;18(35):5476-82. doi: 10.2174/092986711798194388. Curr Med Chem. 2011. PMID: 22087839 Free PMC article. Review.
-
Protein Kinases in Obesity, and the Kinase-Targeted Therapy.Adv Exp Med Biol. 2024;1460:199-229. doi: 10.1007/978-3-031-63657-8_7. Adv Exp Med Biol. 2024. PMID: 39287853 Review.
Cited by
-
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.Br J Haematol. 2010 Oct;151(1):70-83. doi: 10.1111/j.1365-2141.2010.08319.x. Epub 2010 Aug 2. Br J Haematol. 2010. PMID: 20701602 Free PMC article.
-
Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer.J Exp Clin Cancer Res. 2019 Nov 8;38(1):460. doi: 10.1186/s13046-019-1424-4. J Exp Clin Cancer Res. 2019. PMID: 31703744 Free PMC article.
-
Rational Combinations of Targeted Agents in AML.J Clin Med. 2015 Apr 10;4(4):634-664. doi: 10.3390/jcm4040634. eCollection 2015 Apr. J Clin Med. 2015. PMID: 26113989 Free PMC article. Review.
-
CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.Oncogene. 2015 Jun 4;34(23):2978-90. doi: 10.1038/onc.2014.248. Epub 2014 Aug 18. Oncogene. 2015. PMID: 25132270
-
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.Leukemia. 2005 Sep;19(9):1579-89. doi: 10.1038/sj.leu.2403868. Leukemia. 2005. Retraction in: Leukemia. 2016 Jun;30(6):1452. doi: 10.1038/leu.2016.7. PMID: 16015388 Retracted.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous